Ventrus Biosciences (VTUS) IPO Prices at $6
Tweet Send to a Friend
Up)
Ventrus Biosciences Inc. (Nasdaq: VTUS) prices its IPO of 2,900,000 shares at $6.00 per share, the low end of the expected $6-$7 range. The shares will open today on the Nasdaq Capital Market under the symbol "VTUS."
Rodman & Renshaw, LLC, and National Securities Corporation acted as co-lead managing underwriters for the offering.
Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Rodman & Renshaw, LLC, and National Securities Corporation acted as co-lead managing underwriters for the offering.
Ventrus is a development stage specialty pharmaceutical company focused on the development of late-stage prescription drugs for gastrointestinal disorders, specifically hemorrhoids, anal fissures and fecal incontinence.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- UPDATE: Crash in American Electric Power (AEP) & NextEra Energy (NEE) Adds to Jitters
- SHAREHOLDER ALERT: Pomerantz Law Firm Has Filed a Class Action Against Ventrus Biosciences, Inc. and Certain Officers -- VTUS
- Highway Holdings (HIHO) Halted Again on Circuit Breaker; Last Up 80%
Create E-mail Alert Related Categories
IPOs, Trader TalkRelated Entities
Rodman & Renshaw
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
